5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          J Thorac Oncol
          Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
          Elsevier BV
          1556-1380
          1556-0864
          Apr 2016
          : 11
          : 4 Suppl
          Affiliations
          [1 ] Department of Medicine, Section of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
          [2 ] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
          [3 ] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
          [4 ] Respiratory Medicine and Medical Oncology, Japanese National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
          [5 ] Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
          [6 ] Department of Thoracic Oncology, National Cancer Center East, Chiba, Japan.
          [7 ] Department of Oncology, Asan Medical Center, University of Ulsan School of Medicine, Seoul, Republic of Korea.
          [8 ] Oncology, Global Medicine Development, AstraZeneca, Shanghai, China.
          [9 ] Patient Safety, AstraZeneca, Macclesfield, UK.
          [10 ] Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
          Article
          S1556-0864(16)30246-5
          10.1016/S1556-0864(16)30246-5
          27198274
          50a3f208-5e84-4e7c-aabc-f1139014743d
          History

          Comments

          Comment on this article